CorriXR Therapeutics

Company Type: Therapeutics

Main focus: Highly selective CRISPR-Cas therapies for cancer

Company stage: Pre-clinical

Diseases: Solid tumours

Genome-editing tool: CRISPR-Cas

Funding stage: Seed Funding

Location: Newark, Delaware, USA

Website: https://www.corrixr.com/

Pipeline:

Partners:

CorriXR Therapeutics is a pre-clinical-stage therapeutics company that leverages CRISPR-Cas to specifically hit cancer cells - sparing healthy cells - by targeting cancer-specific mutations in a selected target. CorriXR's current lead target is the NRF2 gene.

Corrixr Therapeutics

Your Latest CMN News

CARBON Newsletter (29 October 2024) - Your Latest...

Carbon

Oct. 29, 2024

Some of the best links we picked up around the internet

DTMP-Prime Model Advances Prime Editing...

CMN Briefs

Oct. 29, 2024

Researchers in Iran and Germany have developed a deep-learning model, DTMP-Prime, to improve predictions for Prime Editing (PE) efficiency and pegRNA...

Highlight: In Utero Nanoparticle Delivery Enables...

CMN Briefs

Oct. 28, 2024

Delivering mRNA via acid-degradable nanoparticles offers a new frontier in prenatal gene editing, setting the stage for treatments targeting the root...

CMN Weekly (25 October 2024) - Your Weekly CRISPR...

CMN Weekly

Oct. 25, 2024

Some of the best links we picked up around the internet

CRISPR Plus Drug Treatment Makes Neuroblastoma...

CMN Briefs

Oct. 24, 2024

Researchers in Italy and Australia report a triple combination strategy involving CRISPR that boosts the response of neuroblastoma to immunotherapy.

Long, Pure, Complex, Scalable and Multifunctional...